Dakota Wealth Management Takes Position in Hims & Hers Health, Inc. $HIMS

Key Points

• Dakota Wealth Management has acquired a new stake in Hims & Hers Health, purchasing 7,100 shares valued at approximately $354,000 in the second quarter.
• Hims & Hers Health's stock has experienced mixed ratings from analysts, with Citigroup issuing a "sell" and Canaccord Genuity maintaining a "buy" rating, reflecting a diverse outlook among investors.
• Recent insider trading includes CFO Oluyemi Okupe selling 145,000 shares and CEO Andrew Dudum selling 660,000 shares, indicating significant movements among company leadership.

Dakota Wealth Management acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 7,100 shares of the company's stock, valued at approximately $354,000.

A number of other hedge funds also recently made changes to their positions in HIMS. Geneos Wealth Management Inc. acquired a new position in shares of Hims & Hers Health in the 1st quarter valued at $30,000. UMB Bank n.a. increased its position in shares of Hims & Hers Health by 247.5% during the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after purchasing an additional 933 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Hims & Hers Health during the 1st quarter worth about $41,000. Larson Financial Group LLC increased its position in shares of Hims & Hers Health by 47.7% during the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock worth $42,000 after purchasing an additional 458 shares in the last quarter. Finally, Webster Bank N. A. increased its position in shares of Hims & Hers Health by 229.1% during the 2nd quarter. Webster Bank N. A. now owns 905 shares of the company's stock worth $45,000 after purchasing an additional 630 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Analyst Upgrades and Downgrades

HIMS has been the subject of a number of recent analyst reports. Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Zacks Research cut shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Truist Financial dropped their target price on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a research report on Monday, August 18th. Morgan Stanley reiterated an "equal weight" rating and set a $40.00 target price on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $68.00 price objective on shares of Hims & Hers Health in a report on Friday, September 12th. Two analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Reduce" and an average target price of $38.92.

Hims & Hers Health Stock Up 6.3%

Shares of NYSE:HIMS opened at $58.35 on Monday. Hims & Hers Health, Inc. has a 12 month low of $16.05 and a 12 month high of $72.98. The company's 50-day moving average price is $51.22 and its two-hundred day moving average price is $46.54. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The firm has a market cap of $13.19 billion, a P/E ratio of 72.93, a P/E/G ratio of 3.94 and a beta of 2.14.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The company had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm's revenue was up 72.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Activity

In other news, CFO Oluyemi Okupe sold 145,000 shares of the firm's stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $55.35, for a total value of $8,025,750.00. Following the transaction, the chief financial officer owned 128,984 shares of the company's stock, valued at approximately $7,139,264.40. This trade represents a 52.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Andrew Dudum sold 660,000 shares of the firm's stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the completion of the transaction, the chief executive officer directly owned 2,214,769 shares in the company, valued at $112,023,016.02. This trade represents a 22.96% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,535,090 shares of company stock valued at $78,294,662. 17.71% of the stock is currently owned by insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.